Literature DB >> 10910052

Differential expression of cell surface molecules in prostate cancer cells.

A Y Liu1.   

Abstract

The expression of 119 cell surface molecules was catalogued for three prostate cancer cell lines, LNCaP, PC3, and DU145, all of which were established from metastases. Many of these molecules are common to all three cell lines, whereas some are differentially expressed. More prostate basal epithelial cell-specific than luminal epithelial cell-specific molecules are detected, especially in DU145 and PC3 cells. The cancer cells also express molecules that are not normally associated with prostate epithelial cells. As a population, expression of these molecules appears to be heterogeneous. This heterogeneity may be an inherent property of the population.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10910052

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

1.  Characterization of prostate cell types by CD cell surface molecules.

Authors:  Alvin Y Liu; Lawrence D True
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

2.  Macrophage-dependent cleavage of the laminin receptor α6β1 in prostate cancer.

Authors:  Isis C Sroka; Cynthia P Sandoval; Harsharon Chopra; Jaime M C Gard; Sangita C Pawar; Anne E Cress
Journal:  Mol Cancer Res       Date:  2011-08-08       Impact factor: 5.852

3.  Mechanochemical Disruption Suppresses Metastatic Phenotype and Pushes Prostate Cancer Cells toward Apoptosis.

Authors:  Hakm Y Murad; Heng Yu; Daishen Luo; Emma P Bortz; Gray M Halliburton; Andrew B Sholl; Damir B Khismatullin
Journal:  Mol Cancer Res       Date:  2019-01-07       Impact factor: 5.852

4.  Comparative Secretome Profiling and Mutant Protein Identification in Metastatic Prostate Cancer Cells by Quantitative Mass Spectrometry-based Proteomics.

Authors:  Oh Kwang Kwon; Ju Mi Jeon; Eunji Sung; Ann-Yea Na; Sun Joo Kim; Sangkyu Lee
Journal:  Cancer Genomics Proteomics       Date:  2018 Jul-Aug       Impact factor: 4.069

5.  Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile.

Authors:  Alvin Y Liu; Martine P Roudier; Lawrence D True
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

6.  Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter.

Authors:  Pavlos Msaouel; Ianko D Iankov; Cory Allen; Ileana Aderca; Mark J Federspiel; Donald J Tindall; John C Morris; Michael Koutsilieris; Stephen J Russell; Evanthia Galanis
Journal:  Mol Ther       Date:  2009-09-22       Impact factor: 11.454

7.  Chimeric adenoviral vectors incorporating a fiber of human adenovirus 3 efficiently mediate gene transfer into prostate cancer cells.

Authors:  Miho Murakami; Hideyo Ugai; Natalya Belousova; Alexander Pereboev; Paul Dent; Paul B Fisher; Maaike Everts; David T Curiel
Journal:  Prostate       Date:  2010-03-01       Impact factor: 4.104

8.  Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes.

Authors:  Laura E Pascal; Ricardo Z N Vêncio; Laura S Page; Emily S Liebeskind; Christina P Shadle; Pamela Troisch; Bruz Marzolf; Lawrence D True; Leroy E Hood; Alvin Y Liu
Journal:  BMC Cancer       Date:  2009-12-18       Impact factor: 4.430

9.  Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents.

Authors:  Elena V Shashkova; Shannon M May; Michael A Barry
Journal:  Virology       Date:  2009-09-18       Impact factor: 3.616

10.  Engineered measles virus as a novel oncolytic therapy against prostate cancer.

Authors:  Pavlos Msaouel; Ianko D Iankov; Cory Allen; John C Morris; Veronika von Messling; Roberto Cattaneo; Michael Koutsilieris; Stephen J Russell; Evanthia Galanis
Journal:  Prostate       Date:  2009-01-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.